Skip to content

    Cancer Health Center

    Font Size
    A
    A
    A

    Testicular Cancer Treatment (PDQ®): Treatment - Health Professional Information [NCI] - Treatment Option Overview

    Testicular cancer is broadly divided into seminoma and nonseminoma for treatment planning because seminomatous types of testicular cancer are more sensitive to radiation therapy and chemotherapy and are less prone to distant metastases. Moreover, nonseminomas may include teratomatous elements, which tend to be resistant to chemotherapy and often require surgery for cure. By definition, pure seminomas do not contain elements of teratoma. Therefore, surgery plays a larger role in the management of nonseminomas than in the management of seminomas. Nonseminomatous testicular tumors include:

    • Embryonal carcinomas.
    • Yolk sac tumors.
    • Choriocarcinomas.
    • Teratomas.
    • Mixed germ cell tumors.

    An international germ cell tumor prognostic classification has been developed based on a retrospective analysis of 5,202 patients with metastatic nonseminomatous and 660 patients with metastatic seminomatous germ cell tumors.[1] All patients received treatment with cisplatin- or carboplatin-containing therapy as their first chemotherapy course. The prognostic classification, shown below, was agreed on in 1997 by all major clinical trial groups worldwide. It should be used for reporting clinical trial results of patients with germ cell tumors.

    Recommended Related to Cancer

    Overview

    Coenzyme Q10 (commonly known as CoQ10) is a compound that is made naturally in the body. The body uses it for cell growth and to protect cells from damage that could lead to cancer (see Question 1). Animal studies have shown that CoQ10 helps the immune system work better and makes the body better able to resist certain infections and types of cancer (see Question 5). Clinical trials have shown that CoQ10 helps protect the heart from the damaging side effects of doxorubicin, a drug...

    Read the Overview article > >

    A meta-analysis of treatment outcomes for patients with advanced nonseminoma suggested that 5-year survival rates have improved for those patients with a poor prognosis during the period of 1989 to 2004.[2] In addition to improved therapy, the improvement seen in these survival rates could be the result of publication bias, changes in patient selection in reported clinical trials, or more sensitive staging methods that could migrate less-advanced stages to more-advanced stage categories (i.e., stage migration).

    Good Prognosis

    Nonseminoma:

    • Testis/retroperitoneal primary, and
    • No nonpulmonary visceral metastases, and
    • Good markers-all of:
      • Alpha-fetoprotein (AFP) less than 1,000 ng/mL, and
      • Human chorionic gonadotropin (hCG) less than 5,000 IU/mL (1,000 ng/mL), and
      • Lactate dehydrogenase (LDH) less than 1.5 × the upper limit of normal

      56%-61% of nonseminomas

      5-year progression-free survival (PFS) is 89%; 5-year survival is 92%-94%

    Seminoma:

    • Any primary site, and
    • No nonpulmonary visceral metastases, and
    • Normal AFP, any hCG, any LDH

      90% of seminomas

      5-year PFS is 82%; 5-year survival is 86%

    1 | 2
    Next Article:

    Today on WebMD

    man holding lung xray
    What you need to know.
    stem cells
    How they work for blood cancers.
     
    woman wearing pink ribbon
    Separate fact from fiction.
    Colorectal cancer cells
    Symptoms, screening tests, and more.
     
    Jennifer Goodman Linn self-portrait
    Blog
    what is your cancer risk
    HEALTH CHECK
     
    colorectal cancer treatment advances
    Video
    breast cancer overview slideshow
    SLIDESHOW
     
    prostate cancer overview
    SLIDESHOW
    lung cancer overview slideshow
    SLIDESHOW
     
    ovarian cancer overview slideshow
    SLIDESHOW
    Actor Michael Douglas
    Article